CDEX Inc.: Technology Advancements Increase Functionality and Sensitivity of the ID2 Meth Scanner
TUCSON, AZ--(Marketwire - August 24, 2009) - CDEX Inc. (
The August issue of the Law Enforcement Technology Magazine provides a report on the progress of the ID2 Meth Scanner (pages 46, 48-51). While the article features law enforcement applications, it also references the ID2 Meth Scanner PI (Property Inspection Model) in the context of field testing at a county public health department in Washington State of a Meth Scanner (PI) modified to meet the more restrictive Washington State methamphetamine remediation standards. The results of those and follow up tests will be very helpful in further understanding the limits of the Scanner PI Model's sensitivity.
"The ID2 Meth Scanner is a revolutionary product that provides the law enforcement community with a new tool to help combat the growing problem of methamphetamine use," said Tim Shriver, CDEX COO. "The ID2 Meth Scanner is rapidly evolving, with the help of government agencies such as the county public health department in Washington State, to meet the requirements of both law enforcement and property inspection applications. The Law Enforcement Technology Magazine article provides insight into our improvement process and the culture of our company."
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at [ mphilips@cdex-inc.com ].
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.